S. 2512 — Engrossed in Senate

114th CONGRESS 2d Session S. 2512 AN ACT To expand the tropical disease product priority review voucher program to encourage treatments for Zika virus. 1. Short title This Act may be cited as the Adding Zika Virus to the FDA Priority Review Voucher Program Act. 2. Expanding tropical disease product priority review voucher program to encourage treatments for Zika Virus Disease Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended— (1) by redesignating subparagraph (R) as subparagraph (S); (2) in subparagraph (Q), by striking Filoviruses and inserting Filovirus Diseases; and (3) by inserting after subparagraph (Q) the following: (R) Zika Virus Disease. . Passed the Senate March 17, 2016.Secretary